JLJanghee Lee

Janghee Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Janghee Lee has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Latent profiles of counselor burnout: Associations with self‐discrepancy

    by Isak Kim, Donghun Lee, Janghee Lee, Sang Min Lee

    The purpose of this research study was to identify heterogeneous counselor burnout profiles using a latent profile analysis (LPA) and examine the profiles in association with counselors’ personal and professional self‐discrepancies in counselor qualities. Data from 360 practicing professional counselors were used for analysis. LPA identified four distinct profiles: Well‐Adjusted Counselors (n = 167, 46.4%), Disconnected Counselors (n = 68, 18.9%), Impaired Counselors (n = 22, 6.1%), and Persevering Counselors (n = 103, 28.6%). A series of Chi‐square tests indicated there were significant associations between the burnout profiles and self‐discrepancies in some counselor qualities, such as “open‐minded,” “stable,” “dependable,” “consistent,” “empathic,” “optimistic,” “trustworthy,” and “sociable.” Professional counselors are encouraged to identify their burnout profile and address personal and professional self‐discrepancy, which may affect burnout symptomology.


  • A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.

    by Soong June Bae, Chang-Ik Yoon, So Eun Park, Chi Hwan Cha, Dooreh Kim, Janghee Lee, Sung Gwe Ahn, Hyung Seok Park, Youngup Cho, Joon Jeong

    587 Background: The neutrophil to lymphocyte ratio (NLR) has been reported that is associated with response to treatment and prognosis in breast cancer, but its role is unclear in HER2 positive breast cancer. In this study, the relevance of NLR for treatment efficacy was analyzed in HER2 positive breast cancer patients underwent neoadjuvant therapy. Methods: Pre-treatment NLR was assessed in 546 HER2 positive breast cancer patients divided into three groups according to neoadjuvant treatment regimens: i) chemotherapy alone, ii) chemotherapy plus trastuzumab, and iii) chemotherapy plus trastuzumab and pertuzumab. The cutoff value of NLR was defined as 2.75. We evaluated the correlation of NLR with pathologic complete response (pCR) rate to neoadjuvant treatment regimen. Results: Of all patients, 422 (77.3%) patients were classified as low NLR group (NLR < 2.75) and 124 (22.7%) patients as high NLR group (NLR≥2.75). In the low NLR group, a pCR was achieved in 59 (25.7%) of 230 patients with chemotherapy alone, 69 (57.5%) of 120 patients with chemotherapy plus trastuzumab, and 47 (65.3%) of 72 patients with chemotherapy plus trastuzumab and pertuzumab ( P< 0.001). In the high NLR group, a pCR was achieved 13 (18.8%) of 69 patients with chemotherapy alone, 5 (20.0%) of 25 patients with chemotherapy plus trastuzumab, and 18 (60.0%) of 30 patients with chemotherapy plus trastuzumab and pertuzumab in the high NLR group ( P< 0.001). The pCR rate of chemotherapy plus trastuzumab and chemotherapy plus trastuzumab and pertuzumab was similar, but higher than chemotherapy alone in patients with low NLR. However, only chemotherapy plus trastuzumab and pertuzumab showed high pCR rate compared to chemotherapy alone and chemotherapy plus trastuzumab in patients with high NLR, regardless of hormone receptor status. The elevated NLR was an independent predictor of low pCR rate in patients with chemotherapy plus trastuzumab (OR 0.18, 95% CI, 0.07 to 0.52; P= 0.002), but not in those with chemotherapy alone (OR 0.67; 95% CI, 0.34 to 1.32; P= 0.248; Pinteraction= 0.041) and chemotherapy plus trastuzumab and pertuzumab (OR 0.80; 95% CI, 0.33 to 1.92; P= 0.614; Pinteraction= 0.031). Conclusions: This study identified a possibility of NLR as an easily accessible predictive marker to guide neoadjuvant HER2 target therapy in HER2 positive early breast cancer. Further study with other cohort is needed for validation.